ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1234

Incidence of Conversion of Screening Tests for M. Tuberculosis (PPD, GIF-release assay) in a Metropolitan Cohort of Patients Treated with TNF-α Inhibitors

Hung Trinh and Darren Tabechian, Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, immunosuppressants, Infection, tuberculosis and tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Infection-related Rheumatic Disease Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Tumor necrosis factor alpha (TNF-α) inhibitors are used to reduce the inflammatory process in many autoimmune diseases. Due to the risk of reactivation of latent tuberculosis, screening for latent infection with either purified protein derivative (PPD) skin testing or gamma interferon (GIF) release assay is necessary prior to initiation of treatment. Recommendations for subsequent testing while on TNF-α inhibitors vary, and there is a lack of data regarding the incidence of screening test conversion for patients on TNF-α inhibitors.

Methods:

Between March 29, 2010 and October 19, 2016, patients over the age of 18 who had had an encounter with a rheumatologist at one of the University of Rochester Medical Center rheumatology practice clinics were identified through a search of our electronic medical record. Our physicians provide care for an estimated 60% of the patients in the referral catchment population of approximately 1.1 million residents (including 5 suburban and agricultural counties and a medium sized city of 210,000). The charts of those who had been prescribed a TNF-α inhibitor (adalimumab, certolizumab, etanercept, golimumab, or infliximab) and who had been identified by ICD coding for positive PPD or GIF release assay testing, were reviewed.

Results:

Of the 2807 rheumatology clinic patients treated with TNF-α inhibitors, 89 cases (2.9%) of latent tuberculosis were identified and verified by chart review to have a confirmed positive PPD reading or GIF release assay. 25 (28.1%) of these cases were identified after the initiation of a TNF-α inhibitor as new converters. The rate of PPD or GIF-release assay conversion with TNF-α inhibitor use amongst our cohort is 0.89% (25 of 2807 patients).

Conclusion:

We documented a 0.89% PPD/GIF conversion rate in our patients on TNF-α inhibitors. Our data suggests that continued screening of patients maintained on TNF-α inhibitor therapy will improve identification of these patients unknowingly exposed to mycobacterial infection.


Disclosure: H. Trinh, None; D. Tabechian, None.

To cite this abstract in AMA style:

Trinh H, Tabechian D. Incidence of Conversion of Screening Tests for M. Tuberculosis (PPD, GIF-release assay) in a Metropolitan Cohort of Patients Treated with TNF-α Inhibitors [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/incidence-of-conversion-of-screening-tests-for-m-tuberculosis-ppd-gif-release-assay-in-a-metropolitan-cohort-of-patients-treated-with-tnf-%ce%b1-inhibitors/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-conversion-of-screening-tests-for-m-tuberculosis-ppd-gif-release-assay-in-a-metropolitan-cohort-of-patients-treated-with-tnf-%ce%b1-inhibitors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology